 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
|
|
|
|
October 3, 2000 Company Press Release Galileo Laboratories Expands Senior Management Team, Adding Nutritional Discovery and Clinical DevelopmentGalileo Names Robert A. Lunbeck, Jr. as Chief Financial Officer, Stephen D. Phinney, M.D., Ph.D., as Vice President Clinical Nutrition, and Sekhar S. Boddupalli, Ph.D., as Vice President Nutrition DiscoverySanta Clara, CA, October 03, 2000 – Galileo Laboratories, Inc. has expanded its senior management team as the company advances its Nutritional Discovery and Development programs. This effort will operate alongside Galileo’s Pharmaceutical programs. Galileo has appointed Robert A. Lunbeck, Jr. as Chief Financial Officer. In this position, Mr. Lunbeck is responsible for directing Galileo’s finance activities, investor relations, and planning for the company’s anticipated high growth. Mr. Lunbeck joins Galileo from Chase H&Q, a leading investment bank, where he spent four years as Senior Healthcare Analyst. Previously, Mr. Lunbeck served as Analyst specializing in healthcare at RCM Capital Management, a San Francisco based institutional money manager, and as Vice President, emphasizing biomedical investing, at Security Pacific Venture Capital. Mr. Lunbeck holds an MBA from Stanford University and an A.B. in Economics, Phi Beta Kappa, from Harvard College, and is a Chartered Financial Analyst. Stephen D. Phinney, M.D., Ph.D., joins Galileo as Vice President Clinical Nutrition. Dr. Phinney develops and manages clinical trials for Galileo’s Nutrition programs. Dr. Phinney brings 20 years of design and clinical trials experience in both academic and industry settings. Over 55 of his peer-reviewed publications have appeared in both clinical nutrition and biochemical journals. “Dr. Phinney’s credentials, expertise, and track record will allow Galileo to efficiently conduct state-of-the-art clinical studies incorporating genomics and wireless applications. This competency will greatly advance the development of personalized, bioactive consumer nutrition products that are evidence-based and exceed current regulatory standards," said Guy Miller, M.D., Ph.D., Chief Executive Officer of Galileo. Dr. Phinney holds an M.D. from Stanford University Medical School and a Ph.D. from MIT in Nutritional Biochemistry. He completed a Clinical Nutrition fellowship at Harvard Medical School, and subsequently held clinical faculty appointments at MIT, University of Vermont College of Medicine, University of Minnesota, and as Professor at the University of California at Davis. Also joining the Galileo senior management team as Vice President Nutrition Discovery is Sekhar Boddupalli, Ph.D. Dr. Boddupalli comes from Monsanto Company where he was Director, Human Nutrition. After completing his training in biochemistry at the Indian Institute of Science in Bangalore, Dr. Boddupalli held faculty appointments at the University of Texas, Southwestern Medical Center, Dallas. About Galileo LaboratoriesGalileo Laboratories discovers and develops proprietary nutritional and pharmaceutical products to address such major chronic conditions as cardiovascular disease and diabetes through mitigating metabolic and oxidative stress. Galileo deploys state-of-the-art pharmaceutical and biotechnology tools to screen and develop bioactive compounds for use as functional foods, complementary medicines, and pharmaceuticals. The company possesses proprietary cell-based technology that models the human metabolism, allowing for rapid screening and isolation of therapeutically beneficial compounds, dramatically speeding time-to-market. Galileo clinical studies provide credible evidence of safety and efficacy. Galileo has strategic product development agreements with leading companies in biotechnology, pharmaceuticals and consumer products. This spring, Nutraceuticals World named Galileo, along with McNeil/J&J, General Mills and Quaker Oats, as one of the industry’s top 10 innovators. ContactPeter
Leighton, Vice President Marketing
|
